Elan is a bio/pharmaceutical company with roots in Ireland and the US. It has 2 primary foci: biologic treatments for neurologic indications and drug delivery.
They currently have several sources of revenue:
* Drug delivery manufacturing and R&D contract services
* Nanotechnology drug delivery licensing and manufacturing services
* Older hospital drugs that will gradually come off patent
* Tysabri - a monoclonal antibody product approved by the FDA and pending approval by EMEA for treatment of MS and Crohns Disease. (currently is voluntarily withdrawn pending review of safety data after treatment in combination INFb found to make 2 patients susceptiable to PML.)
* Prialt, an intrathecally delivered synthetic toxin for relieving pain otherwise untreatable by morphine
In R&D are:
* AAB-001 mAb for Alzheimer's Disease
* AAC-001 immunoconjugate for Alzheimer's Disease
* beta secretase program for Alzheimer's Disease
* gamma secretase program for Alzheimer's Disease
* publicly unnamed mAb for treatment of Parkinson's Disease
This thread is now moderated: please be civil and keep the discussion on topic (about Elan.) Shorts and Longs are both welcome with the caveat that cheerleading and slamming without reasoning and sources to back them up are not welcome. |
